肺结核
结核分枝杆菌
疾病
医学
DNA修复
抗药性
药物开发
药品
重症监护医学
免疫学
生物
药理学
DNA
微生物学
遗传学
病理
作者
Pooja Mittal,Rajesh Sinha,Amit Kumar,Pooja Singh,Moses Rinchui Ngasainao,Archana Singh,Indrakant K. Singh
标识
DOI:10.2174/1568026620666200110114322
摘要
Tuberculosis (TB) is one such disease that has become a nuisance in the world scenario and one of the most deadly diseases of the current times. The etiological agent of tuberculosis, Mycobacterium tuberculosis (M. tb) kills millions of people each year. Not only 1.7 million people worldwide are estimated to harbor M. tb in the latent form but also 5 to 15 percent of which are expected to acquire an infection during a lifetime. Though curable, a long duration of drug regimen and expense leads to low patient adherence. The emergence of multi-, extensive- and total- drug-resistant strains of M. tb further complicates the situation. Owing to high TB burden, scientists worldwide are trying to design novel therapeutics to combat this disease. Therefore, to identify new drug targets, there is a growing interest in targeting DNA repair pathways to fight this infection. Thus, this review aims to explore DNA repair and damage tolerance as an efficient target for drug development by understanding M. tb DNA repair and tolerance machinery and its regulation, its role in pathogenesis and survival, mutagenesis, and consequently, in the development of drug resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI